HSE-funded hospitals are getting large sums of money from big pharmaceutical companies which paid out €32.5m last year to a ...

A call has been made for “full transparency” about payments made by drug companies to healthcare professionals and healthcare ...

Professor Michael Barry, Clinical Director of the National Centre for Pharmacoeconomics, is calling for “full transparency” ...

The practice of drug company payments to healthcare professionals and health organisations in Ireland is widespread, a review ...

It has been a challenging couple of days in terms of education costs, with the squeeze coming on for those at both ends of the system. Parents of primary school pupils have been complaining about the ...

Pharmacoeconomics’ impact on Egypt’s oncology treatment evolution Facing constrained budgets and rising incidence of cancer, Egypt has established a specialist oncology committee and is taking ...

President Trump recently signed a new executive order advancing a "most favored nation" (MFN) approach to drug pricing. The policy would link U.S. prices for certain medicines to those paid ...

We appreciate the responses to our Article,1 which suggest that the health cost of paying for new pharmaceuticals in the National Health Service (NHS), estimated at £1·25 million quality-adjusted life ...